News

Dogs with Cancer Could Leave a Lasting Legacy

Publications

AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model.
Avijit Goswami, Barnali Deb, Sandeep Goyal, Abhishek Gosavi, Mukund Mali, Ashwita M. Martis, Princy Khurana, Mukesh Gangar, Digambar Raykar, Ankita Mohanty and Aditya Kulkarni

Molecules. October 2022, 27, 6721

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy.
Mukesh Gangar, Sandeep Goyal, Digambar Raykar, Princy Khurana, Ashwita M. Martis, Avijit Goswami, Ishani Ghoshal, Ketul V. Patel, Yadav Nagare, Santosh Raikar, Apurba Mukherjee, Rajath Cyriac, Jean-François Paquin, Aditya Kulkarni

Bioorganic Chemistry. December 2021, 0045-2068/© 2021 Elsevier Inc.

Conference Abstracts

First-in-class Zα-domain-targeted ADAR1 p150 inhibitor demonstrates potent antitumor efficacy in high IFN syngeneic melanoma
Aditya Kulkarni; Avijit Goswami; Sandeep Goyal; Princy Khurana; Kawaljit Singh; Barnali Deb

Cancer Res (2026) 86 (7_Supplement): 1559.

Combination of AVA-NP-695 and DDRi demonstrates strong synergy resulting in potent anti-tumor activity in rare pediatric cancers.
Aditya Kulkarni; Borja Ruiz-Fernandez de Cordoba; Avijit Goswami; Sandeep Goyal; Kawaljit Singh; Princy Khurana; Alejandro Sweet-Cordero

Cancer Res (2026) 86 (7_Supplement): 7877.

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics